| 摘要 |
<p>The present invention provides a method for treating a condition associated with muscarinic receptor modulation using a 3-[4-(butylthio)-1,2,5-thiadiazol-3-yl]-1-azabicyclo-[2.2.2]octane transdermal formulation. The invention provides desired transdermal 3-[3-(hexylthio)-1,2,5-thiadiazol-4-yl]-1,2,5,6-tetrahydro-1-methylpyridine patch formulations.</p> |
